GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
The band also contributed the song "Would?" to the soundtrack for the 1992 Cameron Crowe film Singles, whose video received an award for Best Video from a Film at the 1993 MTV Video Music Awards. Dirt is often considered as one of the most influential albums to the sludge metal subgenre, which fuses doom metal with hardcore punk. It was voted "Kerrang! Critic's Choice Album of the Year" for 1992. Dirt was also included in the 2005 book 1001 Albums You Must Hear Before You Die. In 2008, Dirt was ranked as the fifth best album released in the previous two decades by Close-Up magazine. In 2011, Joe Robinson of Loudwire named Dirt as one of the best metal albums of the 1990s, alongside other albums such as Megadeth's Rust in Peace and Tool's Ænima, writing "In the battle between metal and grunge, Alice in Chains are a rare band that is embraced by fans of both genres. The most metal of the Seattle bands, they were marketed as metal for 1990's 'Facelift,' then touted as grunge for 1992's 'Dirt.' The band members themselves didn't bother much with labels, they just churned out some of the finest alt-metal with classics like 'Would?,' 'Rooster' and 'Them Bones' leading their charge all the way to the headlining spot on Lollapalooza '93." In October 2011, the album was ranked number one on Guitar World magazine's top ten list of guitar albums of 1992, with The Offspring's Ignition in second place and Bad Religion's Generator in third place. In June 2017, Dirt was ranked at No. 26 on Rolling Stone's list of the "100 Greatest Metal Albums of All Time".
=== Saint Ansbert of Rouen === Earlier reports of stigmatics do exist, however there is a lack of consensus on how the concept of stigmata was understood pre-Saint Francis. St. Ansbert of Rouen (d. 695 AD) could be considered the earliest stigmatic due to the claims of witnesses following his death, first recorded by an anonymous monk in the mid-8th century AD in Vita Sancti Ansberti:
A particular challenge in analysing AlphaFold models is distinguishing genuine topology from structural prediction artefacts. A high confidence score does not by itself guarantee that a predicted chain crossing is correct, and incorrect modelling of termini or flexible regions may change the calculated topology. AlphaKnot 2.0 therefore provides several measures intended to help evaluate a predicted knot, including the pLDDT values of the complete chain and knot core, the confidence near the boundaries of the knot core, and detection of unusually close contacts between Cα atoms. Users can also compare AlphaFold predictions with independently generated ESMFold models for shorter proteins. Because automated analysis at the scale of the AlphaFold database cannot be manually verified structure by structure, AlphaKnot 2.0 introduced a user annotation system. Database entries can be assessed by users as a knot, artifact, or unsure, allowing potentially incorrect predictions to be flagged for further consideration.
Sources: en.wikipedia.org
Plenty of radioactive ruthenium-103, ruthenium-106, and stable ruthenium are formed by the fission process. The ruthenium in PUREX raffinate can become oxidized to form volatile ruthenium tetroxide which forms a purple vapour above the surface of the aqueous liquor. The ruthenium tetroxide is very similar to osmium tetroxide; the ruthenium compound is a stronger oxidant which enables it to form deposits by reacting with other substances. In this way the ruthenium in a reprocessing plant is very mobile, difficult to stabilize, and can be found in odd places. It has been called extremely troublesome and has a notorious reputation as an especially difficult product to handle during reprocessing. Voloxidation combined with cold trap collection of the flue gases could recover the volatile ruthenium tetroxide before it can become a nuisance in further processing. After the radioactive isotopes have had time to decay, recovered ruthenium could be sold at its relatively high market value. In addition, the ruthenium in PUREX raffinate forms a large number of nitrosyl complexes which makes the chemistry of the ruthenium very complex. The ligand exchange rate at ruthenium and rhodium tends to be long, hence it can take a long time for a ruthenium or rhodium compound to react. At Chernobyl, during the fire, the ruthenium became volatile and behaved differently from many of the other metallic fission products. Some of the particles which were emitted by the fire were very rich in ruthenium.
is the heat flux vector. Because it expresses conservation of total energy, this is sometimes referred to as the energy balance equation of continuous media. The first law is used to derive the non-conservation form of the Navier–Stokes equations.
In 2003, Burger King hired the Miami-based advertising agency Crispin Porter + Bogusky (CP+B), which completely reorganized its advertising with a series of new campaigns. CP+B was known for having a hip, subversive tack when creating campaigns for its clients, exactly what BK was looking for. Their strategy centered on a redesigned Burger King character used during the 1970s/1980s Burger King Kingdom children's advertising campaign as a caricatured variation, now simply called "the King". While highly successful, some of CP+B's commercials were derided for perceived sexism or cultural insensitivity. Burger King's new owner, 3G Capital, later terminated the relationship with CP+B in 2011 and moved its advertising to McGarryBowen to begin a new product-oriented campaign with expanded demographic targeting. Additionally, CP+B created a series of new characters like the Subservient Chicken and the faux nu-metal band Coq Roq, featured in a series of viral web-based advertisements on sites such as MySpace and various Burger King corporate pages, to complement various television and print promotional campaigns. One of the more successful promotions that CP+B devised was the creation of a series of three advergames for the Xbox 360. Created by UK-based Blitz Games and featuring company celebrity spokesman Brooke Burke, the games sold more than 3.2 million copies, placing them as one of the top selling games along with another Xbox 360 hit, Gears of War.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.